Non-Small Cell Lung Cancer: A Patient Overview

Non-small cell lung cancer is the most common form of lung cancer and includes subtypes such as adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Treatment depends on stage at diagnosis, tumor location and whether the tumor has genetic changes that can be treated with targeted drugs. Many people benefit from a combination of surgery, chemotherapy, radiation, immunotherapy or targeted therapy. This guide explains typical steps at each stage and is meant to help you prepare questions for your oncology team.

What Does a Diagnosis of Non-Small Cell Lung Cancer Look Like?

A diagnosis of non-small cell lung cancer is usually confirmed after a biopsy of the lung or lymph nodes. Imaging such as CT scans, PET scans or MRIs define the tumor’s size and spread. Molecular testing for gene changes such as EGFR, ALK, ROS1 and KRAS is standard. Those results often determine whether targeted drugs are an option.

What are Non-Small Cell Lung Cancer Treatment Options?

Stage 1

Stage 1 non-small cell lung cancer is limited to the lung and has not spread to lymph nodes or other organs. Many people are treated with surgery to remove the tumor and typically have a favorable outlook. For patients who cannot undergo surgery, stereotactic body radiation therapy can be highly effective. Additional therapy after surgery may be recommended if the tumor has high-risk features.

Frontline

• Surgery (lobectomy or segmentectomy)
• Stereotactic body radiation therapy for nonsurgical candidates

Second-Line

• Adjuvant chemotherapy for higher-risk tumors
• Consideration of clinical trials

Third-Line and Beyond

• Clinical trials
• Systemic therapy tailored to tumor genetics if recurrence occurs

Stage 2

Stage 2 disease usually means a larger tumor or spread to nearby lymph nodes within the lung. Treatment still centers on surgery but more patients receive additional systemic therapy afterward to reduce the risk of recurrence. Radiation may be used based on surgical findings.

Frontline

• Surgery to remove the tumor and affected lymph nodes
• Adjuvant chemotherapy

Second-Line

• Immunotherapy after chemotherapy for eligible patients
• Radiation if margins or nodal disease require it

Third-Line and Beyond

• Clinical trials
• Additional systemic therapy based on prior treatment and tumor biology

Stage 3

Stage 3 non-small cell lung cancer involves more extensive lymph node involvement or tumor extension to nearby structures. Treatment is complex and often multimodal. Many people receive combined chemotherapy and radiation followed by immunotherapy; selected patients may be candidates for surgery after initial treatment if the tumor responds.

Frontline

• Concurrent chemoradiation
• Immunotherapy after chemoradiation for eligible patients

Second-Line

• Surgery for select responders
• Additional systemic therapy based on tumor genetics and prior response

Third-Line and Beyond

• Clinical trials
• Systemic therapy, including targeted agents if a driver mutation is found

Metastatic

Metastatic disease means the cancer has spread to distant organs such as the brain, liver, bones or adrenal glands. Treatment shifts to controlling the cancer, relieving symptoms and preserving quality of life. Many people benefit from targeted therapy when a driver mutation is present. Others receive immunotherapy, chemotherapy or combinations based on tumor markers and overall health.

Frontline

• Targeted therapy for tumors with actionable mutations
• Immunotherapy alone or combined with chemotherapy
• Chemotherapy when targeted options are not available

Second-Line

• Alternate targeted agents based on resistance patterns
• Different immunotherapy or chemotherapy regimens

Third-Line and Beyond

• Antibody-drug conjugates for eligible patients
• Clinical trials
• Supportive and palliative care to manage symptoms and maintain quality of life

Why Molecular Characteristics Matter in Non-Small Cell Lung Cancer

Having detailed molecular information about a tumor helps oncologists match treatment to the disease. Dr. Fred R. Hirsch, Joe Lowe and Louis Price Professor of Medicine at the Icahn School of Medicine at Mount Sinai and executive director of the Center for Thoracic Oncology, told CURE that oncology has moved from a one-size-fits-all approach to personalized medicine.

Hirsch explained in an interview at the IASLC 2025 World Conference on Lung Cancer: “Previously, we gave all patients with lung cancer practically the same type of therapy, and that was typically chemotherapy. Today, we have moved into personalized medicine, which means that we give patients therapy based on the molecular characteristics of the cancer. That means we can group patients with lung cancer by molecular features of the tumor. We have medicines today that target specific mutations, and mutations are the abnormality that drives the tumor. It is important to understand those molecular characteristics, because they guide the therapy we choose and inform prognosis. We want to give the right therapy to the right patients, and one size does not fit all.”

Side effects

Side effects depend on the specific treatments. Chemotherapy may cause fatigue, nausea, hair loss, appetite changes and low blood counts. Immunotherapy can cause inflammation in organs such as the lungs, colon or liver. Targeted drugs may cause rash, diarrhea or liver enzyme changes. Radiation to the chest may cause fatigue, cough or shortness of breath. Most side effects can be managed with supportive care and early reporting to your treatment team.

Conclusion

Treatment for non-small cell lung cancer is increasingly personalized, which often improves outcomes and preserves quality of life. Knowing your stage and the molecular features of your tumor helps you and your oncologist choose the best treatment plan. Use this guide to prompt questions for your team about surgery, systemic therapy, molecular testing and clinical trials. Your oncology team is there to support you at each step.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.